SPINAL MUSCULAR ATROPHY MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Spinal Muscular Atrophy Market - Overview The Global Spinal Muscular Atrophy (SMA) Market, by Disease Type (Type I, Type II, Type III, Type IV) Treatment (Gene Therapy and Drugs), by Age (Infant and Adult),and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was estimated to be valued at US$ 884 million in 2017 and is projected to exhibit a CAGR of 12.4% over the forecast period (2018 – 2026). Spinal muscular atrophy market is expected to grow at significant rate, owing to rising number of clinical trials being conducted to develop effective treatment for the disease. Increasing focus on clinical trials is expected to drive growth of the spinal muscular atrophy (SMA) market Increasing number of clinical trials are being conducted by key industry players and rising government support for these clinical trials is expected to drive growth of the spinal muscular atrophy market. Various clinical studies focus on therapeutic strategies to increase survival motor neuron (SMN) protein in motor neurons since these neurons control muscle movement in the body. Currently, only one approved drug treatment is available for spinal muscular atrophy i.e. Spinraza. In 2016, the U.S. FDA approved Spinraza (nusinersen) drug from Biogen for the treatment of SMA. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/spinalmuscular-atrophy-market-1920 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Several biotechnology and biopharmaceutical giants are working towards developing effective treatment for SMA. For instance, in 2017, AveXis received FDA approval for manufacturing of AVXS-101 gene therapy. It is currently in development stage, and has been granted Orphan Drug Designation in 2017 for the treatment of all types of spinal muscular atrophy (SMA) and Breakthrough Therapy Designation in 2016 for the same. It also received Fast Track Designation in 2016, for the treatment of SMA Type 1—one of the most chronic neurological genetic disorders. In April 2018, AveXis announced launching of a Phase 3 trial, for STR1VE in infants with SMA type 1. AveXis also plans to initiate a similar trial in Europe called STR1VE EU. Browse 32 Market Data Tables and 26 Figures spread through 161 Pages and in-depth TOC on “Spinal Muscular Atrophy Market, by Disease Type (Type I, Type II, Type III, Type IV), by Treatment (Gene Therapy and Drugs), by Age (Infant and Adult), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026” Key players are focusing on mergers and acquisitions, new product launches, and partnerships, in order to enhance their share in the market. For instance, in 2016, Ionis discovered Spinraza and co-developed the drug with Biogen. Ionis received a payment of US$ 320 million from Biogen for the development of Spinraza till the year 2016, including US$ 90 million based on regulatory approvals in Japan and Europe. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/1920 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the Spinal Muscular Atrophy Market: The global spinal muscular atrophy market is expected to exhibit a CAGR of 12.4% over the forecast period, owing to rising number of clinical trials for development of new therapies. Among treatment, the drugs segment is estimated to hold the dominant position in the spinal muscular atrophy market in 2017 due to approval of single drug Spinraza. Among disease type, the type I segment is estimated to hold the dominant position in the spinal muscular atrophy market in 2017. This is owing to it been the most common and severe form of SMA. According to SMA Europe 2015 data, type I accounts for 50% to 70% of cases of childhood onset SMA. North America held a dominant position in 2017 owing to higher demand for spinal muscular atrophy treatment as a result of higher diagnosis rate in the region. Key players operating in the global spinal muscular atrophy market include Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer, and Ionis Pharmaceuticals, Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1920 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
© Coherent market Insights. All Rights Reserved